IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-04122856.html
   My bibliography  Save this paper

Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma

Author

Listed:
  • Béranger Lueza

    (IGR - Institut Gustave Roussy, SBE - Service de biostatistique et d'épidémiologie - Direction de la recherche clinique [Gustave Roussy] - IGR - Institut Gustave Roussy)

  • Anne Aupérin

    (CESP - Centre de recherche en épidémiologie et santé des populations - UVSQ - Université de Versailles Saint-Quentin-en-Yvelines - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Paul Brousse - INSERM - Institut National de la Santé et de la Recherche Médicale - Université Paris-Saclay, IGR - Institut Gustave Roussy, SBE - Service de biostatistique et d'épidémiologie - Direction de la recherche clinique [Gustave Roussy] - IGR - Institut Gustave Roussy)

  • Charlotte Rigaud

    (Département de cancérologie de l'enfant et de l'adolescent [Gustave Roussy] - IGR - Institut Gustave Roussy)

  • T.G. Gross

    (Children’s Hospital Colorado - University of Colorado Anschutz [Aurora])

  • Marta Pillon

    (Unipd - Università degli Studi di Padova = University of Padua)

  • R.F. Delgado

    (UV - Universitat de València)

  • A. Uyttebroeck

    (University Hospitals Leuven [Leuven])

  • Gladstone Austin Amos Burke

    (Addenbrooke's Hospital - Cambridge University NHS Trust)

  • Jõzsef Zsíros

    (Princess Máxima Center for Pediatric Oncology [Utrecht, Netherlands])

  • M. Csóka

    (Semmelweis University [Budapest])

  • Mathieu Simonin

    (CHU Trousseau [APHP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - SU - Sorbonne Université, SU - Sorbonne Université)

  • C. Patte

    (Département de cancérologie de l'enfant et de l'adolescent [Gustave Roussy] - IGR - Institut Gustave Roussy)

  • V. Minard-Colin

    (Département de cancérologie de l'enfant et de l'adolescent [Gustave Roussy] - IGR - Institut Gustave Roussy, IGR - Institut Gustave Roussy, ITIC - Immunologie anti-tumorale et immunothérapie des cancers - IGR - Institut Gustave Roussy - INSERM - Institut National de la Santé et de la Recherche Médicale - Université Paris-Saclay)

  • Julia Bonastre

    (CESP - Centre de recherche en épidémiologie et santé des populations - UVSQ - Université de Versailles Saint-Quentin-en-Yvelines - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Paul Brousse - INSERM - Institut National de la Santé et de la Recherche Médicale - Université Paris-Saclay, IGR - Institut Gustave Roussy, SBE - Service de biostatistique et d'épidémiologie - Direction de la recherche clinique [Gustave Roussy] - IGR - Institut Gustave Roussy)

Abstract

Objectives: The randomized controlled trial Inter-B-NHL ritux 2010 showed overall survival (OS) benefit and event-free survival (EFS) benefit with the addition of rituximab to standard Lymphomes Malins B (LMB) chemotherapy in children and adolescents with high-risk, mature B cell non-Hodgkin's lymphoma. Our aim was to assess the cost-effectiveness of rituximab-chemotherapy versus chemotherapy alone in the French setting. Methods: We used a decision-analytic semi-Markov model with four health states and 1-month cycles. Resource use was prospectively collected in the Inter-B-NHL ritux 2010 trial (NCT01516580). Transition probabilities were assessed from patient-level data from the trial (n = 328). In the base case analysis, direct medical costs from the French National Insurance Scheme and life-years (LYs) were computed in both arms over a 3-year time horizon. Incremental net monetary benefit and cost-effectiveness acceptability curve were computed through a probabilistic sensitivity analysis. Deterministic sensitivity analysis and several sensitivity analyses on key assumptions were also conducted, including one exploratory analysis with quality-adjusted life years as the health outcome. Results: OS and EFS benefits shown in the Inter-B-NHL ritux 2010 trial translated into the model by rituximab-chemotherapy being the most effective and also the least expensive strategy over the chemotherapy strategy. The mean difference in LYs between arms was 0.13 [95% CI 0.02; 0.25], and the mean cost difference € − 3 710 [95% CI € − 17,877; € 10,525] in favor of rituximab-chemotherapy group. For a € 50,000 per LY willingness-to-pay threshold, the probability of the rituximab-chemotherapy strategy being cost-effective was 91.1%. All sensitivity analyses confirmed these findings. Conclusion: Adding rituximab to LMB chemotherapy in children and adolescents with high-risk mature B-cell non-Hodgkin's lymphoma is highly cost-effective in France. Trial registration: ClinicalTrials.gov identifier: NCT01516580.

Suggested Citation

  • Béranger Lueza & Anne Aupérin & Charlotte Rigaud & T.G. Gross & Marta Pillon & R.F. Delgado & A. Uyttebroeck & Gladstone Austin Amos Burke & Jõzsef Zsíros & M. Csóka & Mathieu Simonin & C. Patte & V. , 2023. "Cost-effectiveness analysis alongside the inter-B-NHL ritux 2010 trial: rituximab in children and adolescents with B cell non-Hodgkin’s lymphoma," Post-Print hal-04122856, HAL.
    • Handle: RePEc:hal:journl:hal-04122856
    DOI: 10.1007/s10198-023-01581-y
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-04122856. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.